Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anti-tobacco law funds new Panama cancer hospital:

This article was originally published in Clinica

Executive Summary

Panama is to part-finance a new hospital specialising in cancer with funds derived from legislation aimed at reducing the incidence of smoking. Panama's oncological hospital is due to receive an additional $3.2 million a year from revenues generated by a 5% rise in tax on tobacco. Panama has clamped down on smoking, in a bid to reduce the burden of smoking-related illnesses. Every day, five people a day die from cancer - related primarily to smoking - which is considered to cost the state $10,000 per patient. The law, approved earlier this month by the legislative assembly, also enforces strict punitive measures aimed at reducing the incidence of smoking. These include fines of up to $1,000 for smoking outside restricted areas, and imprisonment and heavy fines for trafficking.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT071325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel